OBJECTIVES: We sought to evaluate the effect of polymorphisms in the VEGF (Vascular Endothelial Growth Factor) gene on overall survival in ovarian cancer patients. METHODS: A sample of 319 women diagnosed with primary invasive epithelial ovarian cancer in Australia between 1985 and 1997, recruited as incident cases, were genotyped for four VEGF single nucleotide polymorphisms (three tagSNPs and one functional SNP) using the Sequenom MassARRAY platform. A SNP found to be associated with ovarian cancer survival in this sample set was then evaluated in two independent datasets in an attempt to replicate the association. RESULTS: VEGF tagSNPs rs3025033 and rs2146323 were not associated with ovarian cancer survival in the Australian sample. Ovarian cancer patients homozygous for tagSNP rs833068 or the functional SNP rs2010963 displayed significantly shortened overall survival in the Australian sample (HR 2.09, 95% CI 1.16-3.78), an effect most apparent in the first 5years after diagnosis. This association was not replicated in two independent datasets. CONCLUSIONS: Findings from this study provide no evidence that rs3025033 and rs2146323 VEGF polymorphisms are associated with ovarian cancer survival. Although homozygous carriers of the tagSNP rs833068 experienced significantly worse survival in our Australian dataset, we were unable to replicate this in two independent datasets.
OBJECTIVES: We sought to evaluate the effect of polymorphisms in the VEGF (Vascular Endothelial Growth Factor) gene on overall survival in ovarian cancerpatients. METHODS: A sample of 319 women diagnosed with primary invasive epithelial ovarian cancer in Australia between 1985 and 1997, recruited as incident cases, were genotyped for four VEGF single nucleotide polymorphisms (three tagSNPs and one functional SNP) using the Sequenom MassARRAY platform. A SNP found to be associated with ovarian cancer survival in this sample set was then evaluated in two independent datasets in an attempt to replicate the association. RESULTS:VEGF tagSNPs rs3025033 and rs2146323 were not associated with ovarian cancer survival in the Australian sample. Ovarian cancerpatients homozygous for tagSNP rs833068 or the functional SNP rs2010963 displayed significantly shortened overall survival in the Australian sample (HR 2.09, 95% CI 1.16-3.78), an effect most apparent in the first 5years after diagnosis. This association was not replicated in two independent datasets. CONCLUSIONS: Findings from this study provide no evidence that rs3025033 and rs2146323VEGF polymorphisms are associated with ovarian cancer survival. Although homozygous carriers of the tagSNP rs833068 experienced significantly worse survival in our Australian dataset, we were unable to replicate this in two independent datasets.
Authors: Kimberly E Alexander; Suzanne Chambers; Amanda B Spurdle; Jyotsna Batra; Felicity Lose; Tracy A O'Mara; Robert A Gardiner; Joanne F Aitken; Judith A Clements; Mary-Anne Kedda; Monika Janda Journal: Qual Life Res Date: 2015-02-28 Impact factor: 4.147
Authors: Felicity Lose; Srilakshmi Srinivasan; Tracy O'Mara; Louise Marquart; Suzanne Chambers; Robert A Gardiner; Joanne F Aitken; Amanda B Spurdle; Jyotsna Batra; Judith A Clements Journal: PLoS One Date: 2012-09-06 Impact factor: 3.240
Authors: Jyotsna Batra; Christina M Nagle; Tracy O'Mara; Melanie Higgins; Ying Dong; Olivia L Tan; Felicity Lose; Lene Marie Skeie; Srilakshmi Srinivasan; Kelly L Bolton; Honglin Song; Susan J Ramus; Simon A Gayther; Paul D P Pharoah; Mary-Anne Kedda; Amanda B Spurdle; Judith A Clements Journal: BMC Cancer Date: 2011-04-01 Impact factor: 4.430